养血清脑颗粒剂治疗脑动脉硬化症患者的临床观察

Clinical Observation on Effect of Yangxue Qingnao Granule in Treating Patients with Cerebral Arteriosclerosis

目的 观察养血清脑颗粒剂治疗脑动脉硬化症的疗效,并探讨其机制。方法 167例脑动脉硬化症患者随机分为治疗组(在常规西药治疗的基础上加用养血清脑颗粒剂)和对照组(单用常规西药治疗),观察两组患者治疗前后主要症状积分、脑动脉平均血流速度(VM)及血浆一氧化氮(NO)、降钙素基因相关肽(CGRP)和内皮素(ET)水平的变化。结果 (1)治疗后治疗组眩晕、头痛和耳呜等主要症状积分值均显著低于对照组(P<0.05或P<0.01)。(2)与治疗前比较,治疗组治疗后血浆NO和CGRP显著增高(P<0.01),ET水平和VM显著下降(P<0.01),对照组上述指标无显著变化。结论 养血清脑颗粒剂对脑动脉硬化症有较好的疗效,调控血管活性物质水平是其治疗作用的重要机制。

To observe the efficacy of Yangxue Qingnao granule (YXQN) in treating cerebral arteriosclerosis and to explore its mechanisms. Methods One hundred and sixty-seven patients with arteriosclerosis were randomly divided into the treated group treated with conventional medical treatment plus YXQN and the control group treated with conventional medical treatment alone, to observe the changes before and after treatment in scores of chief symptoms, mean velocity of cerebral blood flow (VM) , plasma nitric oxide (NO), calcitonin gene related peptide (CGRP) and endothelin (ET) levels. Results (1) After treatment in treated group, the scores of chief symptoms such as vertigo, headache and tinnitus were significantly lower than those in the control group (P<0.05 or P<0.01); (2) NO and CGRP level in the treated group after treatment obviously elevated, and ET and VM markedly reduced (P<0.01) , while no evident change of these parameters was found in the control group (P< 0.01). Conclusion The efficacy of YXQN in treating cerebral arteriosclerosis is definite, modulating the level of vasoactive factors was its important mechanism.